Duncan Moore

Duncan Moore

Director/Board Member bij ASP ISOTOPES INC.

Vermogen: 3 M $ op 29-02-2024

65 jaar
Health Technology
Consumer Services
Finance

Profiel

Duncan Moore formally joined East West Capital Partners in May 2008 having served informally as an advisor since early 2007.Duncan Chairs the Scottish Lifesciences Association.
He is the Chairman of Lamellar Biomedical, a Scottish also an investor director of Cambridge based rare disease company focused on upper respiratory diseases, and also Chairman of Allarity Therapeutics A/S, a Swedish company which seeks to bring cancer drugs to the market.
Duncan currently Chairs the Advisory Board of the Scottish LIfesciences Association.
Cycle Pharma, the South African radio isotope manufacturer ASP Isotope and the Dublin based psychedelic drug developer GH Research.
Duncan was a top ranked pharmaceutical analyst at Morgan Stanley from 1991 to 2008 and was a Managing Director from 1997 to 2008 leading the firm’s global healthcare equity research team.
He was the lead analyst on the European pharmaceutical industry stocks and led the equity research part of the initial public offerings of numerous companies including Wellcome PLC, Sulzer Medica, Biora, deCODE Genetics, Almirall, Grifols and, Grupo Rovi.
Whilst at the University of Cambridge he co-founded a medical diagnostics company called Ultra Clone with two colleagues which led to the beginnings of a 20 year career in healthcare capital markets analysis.
In 1986 he was involved in setting up the Bank Invest biotechnology funds and was on a member of the scientific advisory board.Duncan was educated in Edinburgh and went to the University of Leeds where he studied Biochemistry and Microbiology.
He has an M.Phil and Ph.D.
from the University of Cambridge where he was also a post doctoral research fellow.

Bekende belangen in openbare bedrijven

OndernemingDatumAantal aandelenTotale waardeWaarderingsdatum
27-10-2023 854 167 ( 1.75% ) 3 M $ 29-02-2024

Actieve functies van Duncan Moore

BedrijvenFunctieBegin
FORWARD PHARMA A/S Director/Board Member 06-05-2016
GH RESEARCH PLC Director/Board Member 24-09-2021
ASP ISOTOPES INC. Director/Board Member 01-10-2021
Director/Board Member 27-06-2014
Chairman -
Director/Board Member -
Chairman 01-01-2013
Corporate Officer/Principal -
Private Equity Investor 01-05-2008
░░░░░░░░ ░░░░░░░░░░░░ ░░░░░░ ░░░ ░░░░░░░░ ░░░░░░░░░░
Alle actieve functies van Duncan Moore

Eerdere bekende functies van Duncan Moore

BedrijvenFunctieEinde
░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ ░░░░░░░░ ░░░░░░░░░░
░░░░░░ ░░░░░░░ ░░░░░ ░░░ ░░░░░░░░░░░░░ ░░░ ░░░░░░░░░░░░░░ ░░░░░░░░░░
░░░░░░░░ ░░░░░░░ ░░░░░░ ░░ ░░░░░░░░ -
░░░░░░░░░░ ░░░░ ░░░░░░░░ -
░░░░░░░░ ░░░░░░░░░░░░ ░░░ ░░░░░░░░ -
Ervaring van Duncan Moore in detail bekijken

Opleiding van Duncan Moore

University of Cambridge Doctorate Degree
University of Leeds Undergraduate Degree

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Ervaring van Duncan Moore in detail bekijken

Connecties

100 +

Eerstegraads connecties

19

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Persoonlijk netwerk weergeven

Verwante bedrijven

Beursgenoteerde bedrijven3
ALLARITY THERAPEUTICS, INC.

Health Technology

GH RESEARCH PLC

Health Technology

ASP ISOTOPES INC.

Health Technology

Bedrijven in privébezit13

Finance

Commercial Services

Health Technology

Finance

Health Technology

Health Technology

Commercial Services

Health Technology

Consumer Services

Health Technology

Health Technology

Health Technology

Ultraclone Ltd.

Zie bedrijfsconnecties
  1. Beurs
  2. Insiders
  3. Duncan Moore